To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a
reasonable regimen for subsequent research.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03019276
Ages eligible for Study
18 Years to 70 Years
Genders eligible for Study
Accepts Healthy Volunteers
Histological documentation of Advanced solid tumors
Lack of the standard treatment or treatment failure
18-70years,ECOG PS:0-1,Life expectancy of more than 3 months
Main organs function is normal
Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
Patients should participate in the study voluntarily and sign informed consent
Patients with treatment failure by ALK/ROS1 inhibitor
Patients with anti-teratment,radiotherapy or surgery within 4 weeks
Patients participated in other anticancer drug clinical trials within 4 weeks or ALK/ROS1 inhibitor within 1 week
Blood pressure unable to be controlled(systolic pressure>140 mmHg，diastolic pressure>90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥470ms)
Patients with non-healing wounds or fractures
Patients with drug abuse history and unable to get rid of or Patients with mental disorders
History of immunodeficiency
Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
All locations for NCT03019276
Sir Run Run Shaw Hospital,School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310016
Put me in touch!
View full eligibility
Tris trial is registered with FDA with number: NCT03019276. The sponsor of the trial is Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and it is looking for 20 volunteers for the current phase.
Official trial title: Phase I Study of Tolerance and Pharmacokinetics of TQ-B3101 in Patients With Advanced Cancer
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.